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Abstract 
Background: Subclinical left ventricular (LV) diastolic dysfunction in type 2 diabetes (T2D) is a common finding and 
represents an early sign of diabetic cardiomyopathy. However, the relationship between LV diastolic dysfunction and 
the incident T2D has not been previously studied.
Methods: A total of 1817 non‑diabetic participants (mean age, 54 years; 48% men) from the Korean Genome and 
Epidemiology Study who were free of cardiovascular disease were studied. LV structure and function were assessed 
by conventional echocardiography and tissue Doppler imaging. Subclinical LV diastolic dysfunction was defined using 
age‑specific cutoff limits for early diastolic (Em) velocity, mitral E/Em ratio, and left atrial volume index.
Results: During the 6‑year follow‑up period, 273 participants (15%) developed T2D. Participants with incident T2D 
had greater LV mass index (86.7 ± 16.4 vs. 91.2 ± 17.0 g/m2), worse diastolic function, reflected by lower Em velocity 
(7.67 ± 1.80 vs. 7.47 ± 1.70) and higher E/Em ratio (9.19 ± 2.55 vs. 10.23 ± 3.00), and higher prevalence of LV diastolic 
dysfunction (34.6 vs. 54.2%), compared with those who did not develop T2D (all P < 0.001). In a multivariate logistic 
regression model, lower Em velocity (odd ratio [OR], 0.867; 95% confidence interval [CI] 0.786–0.957) and the presence 
of LV diastolic dysfunction (OR, 1.617; 95% CI 1.191–2.196) were associated with the development of T2D, after adjust‑
ing for potential confounding factors.
Conclusions: In a community‑based cohort, the presence of subclinical LV diastolic dysfunction was a predictor of 
the progression to T2D. These data suggest that the echocardiographic assessment of LV diastolic function may be 
helpful in identifying non‑diabetic subjects at risk of incident T2D.
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Background
Recent advances in cardiovascular imaging technology 
have facilitated the detection of underlying subclinical 
target organ damage, which is useful for both the pre-
diction of future cardiovascular disease (CVD) and risk 
stratification even in asymptomatic individuals with type 
2 diabetes (T2D) [1, 2]. From a large body of experi-
mental and clinical studies, it is already recognized that 
T2D is associated with various types of subclinical tar-
get organ damage resulting in an elevated risk of CVD 
events [3–5]. Moreover, there is growing evidence that a 
prediabetic status, such as impaired fasting glucose and 
impaired glucose tolerance, is also related to subclini-
cal target organ damage when compared to a group with 
normal glucose metabolism (NGM) [6, 7].
Among the various forms of preclinical target organ 
damage observed in T2D, impaired left ventricular (LV) 
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diastolic function, assessed using the combination of 
conventional and tissue Doppler imaging (TDI) echocar-
diography, is known to be an early sign of diabetic car-
diomyopathy, even in the presence of normal LV systolic 
function [8]. Indeed, according to the typical sequence of 
the occurrence of target organ damage and T2D as indi-
cated by the traditional CV continuum, T2D should ante-
date the development of subclinical target organ damage, 
such as LV diastolic dysfunction. However, considering 
recent studies and the available data on the association 
between prediabetes and an increased risk of CV events 
[9, 10], the presence of preclinical target organ damage 
in prediabetic patients seems to play an important role 
similar to that of T2D. In addition, in a recent study, the 
presence of subclinical target organ damage, including 
LV hypertrophy and carotid atherosclerosis, was shown 
to be a significant predictor of the development of new 
onset diabetes in hypertensive patients, independent of 
traditional CV risk factors [2]. However, it is still unclear 
whether the presence of asymptomatic target organ 
damage could help to identify sub-populations of non-
diabetic individuals who are at increased risk of incident 
T2D. Accordingly, the present analysis was designed to 
evaluate the prospective relation between the presence of 
baseline LV diastolic dysfunction and the development of 
T2D in the general population.
Methods
Study population
Study subjects were recruited from an ongoing pop-
ulation-based Ansan cohort embedded in the Korean 
Genome Epidemiology Study, as previously described in 
detail [11]. The baseline cohort population (cycle 1) com-
prised 5020 members and has been followed biennially. 
This 6-year follow-up study (cycles 4–7) included the 
3255 individuals who participated in the fourth cycle of 
the 2-year follow-up study (cycle 4) from March 12, 2007 
to April 15, 2009 since the first echocardiographic study 
was performed at examination cycle 4. Those with known 
T2D and unavailable data on baseline glucose tolerance 
results were excluded at baseline (n  =  721). Among 
2,534 participants, we excluded if they had incomplete 
echocardiography data (n  =  302); known CVD includ-
ing previous history of myocardial infarction, coronary 
revascularization, angina, congestive heart failure, stroke, 
congenital heart disease, cardiomyopathy, significant 
valvular heart disease, arrhythmia, and an ejection frac-
tion <50% (n = 26); or a serum creatinine level ≥2.0 mg/
dL (n =  3). Additionally, non-diabetic participants who 
did not take part in the last visit (cycle 7) were also 
excluded (n =  518), leaving a total of 1817 subjects for 
the analysis.
The protocol of the study was approved by the Human 
Subjects Review Committee at the Korea Univer-
sity Ansan Hospital and all participants gave written 
informed consent.
Measurements and definitions
Clinical information on demographics, CV risk factors, 
and medical history was obtained using interviewer-
administered questionnaires. Family history of diabetes 
was defined as having a first-degree relative with diabe-
tes. Height (cm) and body weight (kg) were measured 
and body mass index (BMI, kg/m2) was calculated. Sub-
jects with BMI ≥23 kg/m2 were regarded as overweight 
according to Asian criteria [12]. Blood pressure was 
measured according to a standardized protocol using 
a mercury sphygmomanometer. According to the cur-
rent guidelines, hypertension was defined as a systolic 
blood pressure ≥140 mmHg and/or diastolic blood pres-
sure  ≥90  mmHg and/or use of antihypertensive medi-
cation. After an at least an 8- to 14-h overnight fast, 
blood samples were collected for the measurement of 
serum total cholesterol, high-density lipoprotein (HDL) 
cholesterol, triglycerides (TG), fasting plasma glucose, 
fasting insulin, HbA1c, serum creatinine, and high-
sensitivity C-reactive protein (hsCRP). The homeostasis 
model assessment insulin resistance index (HOMA-IR) 
was calculated as fasting serum insulin (µU/mL) ×  fast-
ing plasma glucose (mg/dL)/405. In order to assess glu-
cose tolerance status, all participants without known 
T2D underwent a 2-h 75-g oral glucose tolerance test at 
inclusion (cycle 4) and then biennially during a 6-year 
period. The definitions of NGM, prediabetes, and T2D 
were made according to 2016 ADA criteria [1]. NGM was 
defined as the presence of the following: a fasting plasma 
glucose  <100  mg/dL, a 2-h plasma glucose  <140  mg/
dL, and HbA1c  <5.7%. Prediabetes was defined as hav-
ing impaired fasting glucose (fasting plasma glucose of 
100–125 mg/dL) and/or impaired glucose tolerance (glu-
cose of 140–199 mg/dL on a 2-h 75-g oral glucose toler-
ance test) and/or HbA1c of 5.7–6.4%. Incident T2D was 
defined as a fasting plasma glucose ≥126  mg/dL, a 2-h 
postprandial plasma glucose ≥200 mg/dL, HbA1c ≥6.5% 
or self-reported current use of anti-diabetic drugs or 
insulin at any follow-up examination cycle.
Echocardiography
All echocardiographic examinations were performed 
using the Vivid 7 system (GE Vingmed, Horton, Nor-
way) with a 4-MHz transducer according to the current 
recommendations [13]. Cardiac chamber diameters and 
wall thickness were measured by M-mode echocardiog-
raphy. The area-length method and Devereux formula 
were used to calculate the left atrial (LA) volume and LV 
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mass, respectively. Both LA volume and LV mass were 
indexed to body surface area and expressed as LA volume 
index and LV mass index. LV ejection fraction measure-
ment was obtained using the modified biplane Simpson’s 
method. Transmitral peak E and peak A diastolic veloci-
ties and early mitral flow deceleration time (DT) were 
recorded at the tips of the mitral valve leaflets in an api-
cal 4-chamber view. Tissue Doppler imaging of both peak 
systolic (Sm) and peak early diastolic (Em) velocities was 
measured at the septal side of the mitral annulus. Subse-
quently, the mitral E/Em ratio was calculated as an index 
of LV diastolic filling pressure. Echocardiographic LV 
hypertrophy was defined as an LV mass index >95 g/m2 in 
women and >115 g/m2 in men. LV diastolic dysfunction 
was defined based on a reduced septal TDI Em velocity, 
septal E/Em ratio >15, or LA volume index ≥34 mL/m2 
[14]. To define a reduced septal TDI Em velocity, an age-
specific abnormal value for septal TDI Em velocity was 
calculated as a value greater than one standard deviation 
below the mean reference value adjusted for age, since 
the TDI Em velocity is highly dependent on age [4, 15].
Statistical analysis
Baseline demographic and echocardiographic data were 
presented as means ± standard deviations for continuous 
variables or as percentages for categorical variables. Dif-
ferences between groups stratified by incident T2D were 
assessed using the Student’s t test for continuous variables 
or the χ2 test for categorical variables. Additionally, uni-
variate logistic regression analyses were used to estimate 
the odds ratios of known cardiometabolic risk factors and 
echocardiographic parameters for the development of 
T2D. Finally, a multivariate logistic regression model tested 
the predictive value of each of the echocardiographic vari-
ables and the presence of baseline LV diastolic dysfunc-
tion for progression to T2D using age, sex, BMI ≥23 kg/
m2, baseline glucose metabolism (NGM vs. prediabetes), 
hypertension, statin therapy, family history of diabetes, 
smoking status, alcohol intake, HOMA-IR, total choles-
terol, TG/HDL ratio, and hsCRP as potential confound-
ers. Covariates for the multivariate model were selected 
on the basis of univariate analyses and known risk factors 
for diabetes proposed by the latest diabetes guidelines [1]. 
To examine the effect of baseline glucose status, we per-
formed additional multivariate logistic regression analyses 
after stratifying participants into two groups: “NGM” and 
“prediabetes”. For the multiple hypotheses testing, we cor-
rected P values using the Bonferroni method based on the 
raw P values of logistic regression.
A P value < 0.05 was considered significant for all anal-
yses. SAS version 9.3 (SAS institute, Cary, NC, USA) was 
used for all analyses.
Results
Baseline demographic, metabolic, and echocardiographic 
characteristics
Table  1 shows the baseline characteristics of the study 
subjects after stratification by incident T2D. Among the 
1817 subjects without known CVD, 788 (43.4%) par-
ticipants had NGM and 1029 (56.6%) had prediabetes 
at baseline according to ADA recommendations. Over 
the 6-year of follow-up period, 273 (129 males and 144 
females) new cases of T2D occurred and 244 participants 
with incident T2D were prediabetic at inclusion. Over-
all, the subjects who developed incident T2D subjects 
displayed significant disturbances in various metabolic 
profiles at baseline, compared to participants without 
incident T2D. However, groups did not differ with regard 
to gender, heart rate, alcohol consumption, total choles-
terol, and serum creatinine.
Table  2 shows that the participants developing T2D 
had higher baseline relative wall thickness, LV mass 
index, mitral inflow A velocity, DT, and E/Em ratio, with 
lower baseline mitral inflow E velocity, mitral inflow E/A 
ratio, and TDI Sm and Em velocities compared to those 
without incident T2D (all P  <  0.05). The prevalence of 
LV hypertrophy and LV diastolic dysfunction was also 
higher in participants developing T2D (all P < 0.05). On 
the other hand, no significant differences in terms of LA 
volume index and LV ejection fraction were shown.
Independent predictors of incident T2D
After 6  years, the development of T2D was associated 
with baseline age, excessive body weight, the presence 
of prediabetes and hypertension, statin therapy, current 
smoking, HbA1c, HOMA-IR, low HDL-cholesterol level, 
high TG level, hsCRP, and family history of diabetes in 
univariate analyses (all P < 0.05).
Table 3 shows that various echocardiographic LV struc-
tural and functional parameters except for LA volume 
index and the presence of LV hypertrophy and LV dias-
tolic dysfunction were independent predictors for the 
development of T2D in univariate analyses. When each 
echocardiographic parameter was separately forced into 
a multivariate logistic regression model including age, 
sex, BMI ≥23 kg/m2, baseline glucose metabolism (NGM 
vs. prediabetes), hypertension, statin therapy, family his-
tory of diabetes, smoking status, alcohol intake, HOMA-
IR, TG/HDL ratio, and hsCRP, only TDI Em velocity 
was inversely and independently associated with inci-
dent T2D. Similarly, the risk of 6-year incidence of T2D 
increased by 62% in the presence of baseline LV diastolic 
dysfunction, regardless of baseline glucose metabolism 
status (Table 3). None of the echocardiographic measure-
ments of LV systolic function showed significant predic-
tive effect.
Page 4 of 8Park et al. Cardiovasc Diabetol  (2017) 16:36 
The multivariate logistic regression analyses, adjusting 
for age, sex, BMI ≥23 kg/m2, fasting plasma glucose, 2-h 
plasma glucose, mean blood pressure, family history of 
diabetes, smoking status, alcohol intake, HOMA-IR, total 
cholesterol, TG/HDL ratio, and hsCRP, were also per-
formed in a specific subpopulation stratified according to 
the baseline glucose metabolism (NGN vs. prediabetes). 
Prediabetic individuals were older, more frequent alcohol 
drinker, had higher baseline BMI, systolic and diastolic 
blood pressures, heart rate, total cholesterol, triglycer-
ides, hsCRP, lower HDL-cholesterol, and more frequent 
family history of diabetes (all P < 0.05) than participants 
with NGM. In the prediabetic population, incident T2D 
was independently predicted by the presence of LV 
diastolic dysfunction, but any of the echocardiographic 
parameters, even with the presence of LV diastolic dys-
function, could not predict the development of T2D in 
subjects with NGM (Table 4).
In a subgroup analysis, we conducted post hoc power 
analyses using GPower software with power at 0.80 and 
alpha = 0.05 (two-tailed) to estimate the sample sizes for 
LV diastolic parameters and the presence of LV diastolic 
function. This showed us that the sample sizes in NGM 
group would have to increase up to 14,132 and 311,264 
for TDI Em velocity and LV diastolic dysfunction, respec-
tively, to reach statistical significance at the 0.05 level. 
Therefore, it is unlikely that our negative results in sub-
jects with NGM can be attributed to a limited sample 
size.
Discussion
We found that the presence of LV diastolic dysfunction, 
one of the various types of target organ damage induced 
by overt T2D, was a significant predictor of incident T2D, 
independent of various cardiometabolic profiles. In addi-
tion, LV diastolic markers such as mitral inflow E/A ratio, 
TDI Em velocity, and E/Em ratio as continuous vari-
ables were also associated with an increased incidence of 
T2D. This finding was confirmed in a subgroup of pre-
diabetes, whereas neither LV diastolic parameters nor 
Table 1 Baseline demographic and  laboratory characteristics of  the study participants developing or not developing 
type 2 diabetes at the follow-up
BMI body mass index, BP blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment-insulin resistance, hsCRP high sensitivity C-reactive 
protein, NGM normal glucose metabolism
Variable All participants (n = 1817) Not developing type 2 diabetes 
(n = 1544)
Developing type 2 diabetes 
(n = 273)
P value
Age (years) 53.5 ± 6.7 53.1 ± 6.4 55.7 ± 7.5 <0.001
Male (%) 47.9 48.1 47.3 0.844
BMI (kg/m2) 24.5 ± 2.7 24.3 ± 2.6 25.4 ± 2.8 <0.001
Systolic BP (mmHg) 110.3 ± 13.5 109.4 ± 13.3 115.1 ± 13.6 <0.001
Diastolic BP (mmHg) 74.6 ± 9.5 74.3 ± 9.6 76.1 ± 9.1 0.002
Heart rate (bpm) 65.0 ± 6.9 64.9 ± 6.9 65.4 ± 6.9 0.318
Hypertension (%) 22.1 19.7 35.9 <0.001
Antihypertensive therapy (%) 16.8 14.5 29.7 <0.001
Fasting glucose (mg/dL) 90.9 ± 8.4 89.9 ± 7.8 96.3 ± 9.7 <0.001
2‑h glucose (mg/dL) 134.3 ± 30.6 129.8 ± 28.4 160.0 ± 29.7 <0.001
Fasting insulin (µIU/mL) 8.70 ± 4.03 8.52 ± 3.99 9.71 ± 4.12 <0.001
HbA1c (%) 5.43 ± 0.35 5.39 ± 0.33 5.65 ± 0.38 <0.001
HOMA‑IR 1.97 ± 0.98 1.91 ± 0.95 2.33 ± 1.06 <0.001
Family history of diabetes (%) 17.5 16.6 22.7 0.016
Glucose metabolism (%) <0.001
 NGM 43.4 49.2 10.6
 Prediabetes 56.6 50.8 89.4
Current smoker (%) 13.5 14.3 9.2 0.021
Current alcohol drinker (%) 50.0 50.1 49.5 0.896
Total cholesterol (mg/dL) 202.5 ± 34.2 202.1 ± 34.5 204.8 ± 32.9 0.217
HDL‑cholesterol (mg/dL) 45.5 ± 10.6 45.9 ± 10.6 43.5 ± 10.5 0.001
Triglycerides (mg/dL) 134.6 ± 83.0 129.6 ± 79.5 162.3 ± 96.1 <0.001
Statin therapy (%) 2.5 1.4 3.4 0.007
hsCRP (mg/L) 1.39 ± 4.17 1.28 ± 3.93 2.03 ± 5.31 0.006
Creatinine (mg/dL) 0.95 ± 0.15 0.95 ± 0.14 0.96 ± 0.16 0.282
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the existence of LV diastolic dysfunction were associated 
with the risk of incident T2D in participants with NGM.
Association of CV risk factors with target organ damage
According to the CV continuum theory, a clear temporal 
relationship exists whereby various CV risk factors, such 
as hypertension and T2D, generally precede the devel-
opment of target organ damage. However, recent litera-
tures have reported that increased LV mass and arterial 
stiffness are predictors of incident hypertension in both 
normotensive and prehypertensive individuals [16, 17]. 
Moreover, our previous findings demonstrated that the 
clustering of target organ damage types, including LV 
hypertrophy, LV diastolic dysfunction, carotid athero-
sclerosis, and arterial stiffness, substantially increases the 
risk of developing hypertension in the non-hypertensive 
population, irrespective of baseline BP category and obe-
sity status [18]. Similar to previous reports regarding the 
temporal correlation between incident hypertension and 
preclinical types of target organ damage, Izzo et  al. [2] 
reported that the presence of target organ damage, such 
as LV hypertrophy and carotid atherosclerosis, is a sig-
nificant predictor of new-onset T2D in a population of 
treated hypertensive patients. Thus, these findings, which 
Table 2 Baseline echocardioraphic parameters of the study participants developing or not developing type 2 diabetes 
at the follow-up
DT deceleration time, LA left atrium, LV left ventricle
Variable Total (n = 1817) Not developing type 2 diabe-
tes (n = 1544)
Developing type 2 diabetes 
(n = 273)
P value
LA volume index (mL/m2) 26.2 ± 6.3 26.1 ± 6.3 26.7 ± 6.4 0.181
Relative wall thickness 0.37 ± 0.06 0.36 ± 0.06 0.39 ± 0.07 <0.001
LV mass (g) 150 ± 37 149 ± 37 158 ± 38 <0.001
LV mass index (g/m2) 87.3 ± 16.6 86.7 ± 16.4 91.2 ± 17.0 <0.001
LV hypertrophy (%) 13.9 13.1 18.7 0.017
LV ejection fraction (%) 65.0 ± 4.5 65.1 ± 4.5 64.7 ± 4.5 0.235
Mitral inflow velocity
 E, cm/s 0.68 ± 0.15 0.68 ± 0.15 0.66 ± 0.15 0.039
 A, cm/s 0.63 ± 0.17 0.62 ± 0.17 0.70 ± 0.18 <0.001
 E/A ratio 1.15 ± 0.36 1.17 ± 0.37 0.99 ± 0.30 <0.001
 DT, ms 195 ± 47 195 ± 47 200 ± 47 0.091
Tissue Doppler imaging (TDI)
 TDI Sm velocity (cm/s) 7.68 ± 1.29 7.70 ± 1.29 7.47 ± 1.27 0.018
 TDI Em velocity (cm/s) 7.57 ± 1.83 7.67 ± 1.80 7.47 ± 1.70 <0.001
E/Em ratio 9.31 ± 2.62 9.19 ± 2.55 10.23 ± 3.00 <0.001
LV diastolic dysfunction (%) 37.5 34.6 54.2 <0.001
Table 3 Baseline echocardiographic parameters associated with incident type 2 diabetes
BMI body mass index, CI confidence interval, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment-insulin resistance, hsCRP high sensitivity 
C-reactive protein, LA left atrium, LV left ventricle, NGM normal glucose metabolism, OR odds ratio, TDI tissue Doppler imaging, TG triglycerides
a Model was adjusted for age, sex, BMI ≥23 kg/m2, baseline glucose metabolism (NGM vs. prediabetes), hypertension, statin therapy, family history of diabetes, 
smoking status, alcohol intake, HOMA-IR, total cholesterol, TG/HDL ratio, and hsCRP. Each echocardiographic variable was tested separately in a multivariate model
b Corrected P values using Bonferroni method for multiple comparisons
Variables Univariate Multivariatea
OR (95% CI) P value OR (95% CI) P value P valueb
LA volume index (mL/m2) 1.013 (0.993–1.034) 0.189 1.017 (0.995–1.040) 0.133 0.933
LV mass index (g/m2) 1.016 (1.008–1.024) <0.001 1.009 (1.000–1.018) 0.040 0.283
LV hypertrophy (yes vs. no) 1.526 (1.088–2.141) 0.014 1.198 (0.806–1.780) 0.371 1.000
TDI Sm velocity (cm/s) 0.856 (0.772–0.949) 0.003 0.914 (0.816–1.024) 0.119 0.836
TDI Em velocity (cm/s) 0.742 (0.685–0.804) <0.001 0.867 (0.786–0.957) 0.004 0.031
E/Em ratio 1.147 (1.094–1.201) <0.001 1.076 (1.017–1.137) 0.010 0.071
LV diastolic dysfunction (yes vs. no) 2.239 (1.726–2.905) <0.001 1.617 (1.191–2.196) 0.002 0.014
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are different from the traditional concept of CV contin-
uum, suggest that the presence of several types of asymp-
tomatic target organ damage may be helpful in predicting 
incident T2D and hypertension.
Association of glucose metabolism with cardiac function
To our knowledge, no epidemiological study has spe-
cifically linked preclinical LV diastolic dysfunction to 
incident T2D. Instead, previous cross-sectional studies 
have shown that subtle abnormalities of LV systolic and/
or diastolic function, which are key components of the 
progression to diabetic cardiomyopathy, are frequently 
detected in T2D [4, 19–23]. Although the exact causes 
leading to the LV changes in patients with T2D remain 
still unclear, the reduction of coronary flow reserve, met-
abolic abnormality, autonomic dysfunction, and myocar-
dial fibrosis have been reported as possible mechanisms 
of subclinical myocardial damage [24]. Besides these 
data, subclinical LA structural and functional changes 
are also known to be common findings in patients with 
T2D [25–27]. Interestingly, Wang et  al. reported that 
LA energy loss and deformation mechanics are already 
impaired even in T2D patients with normal LA size [27]. 
Overall, the duration of diabetes, diabetic complications, 
hypertriglycemia, obesity status, blood pressure, and gly-
cemic control in asymptomatic patients with T2D were 
closely related to LA remodeling and LV diastolic dys-
function. However, according to recent observations, the 
high prevalence of subclinical LV systolic and/or diastolic 
dysfunction has been noted in prediabetic subjects com-
pared to those with normal glucose metabolism, although 
prediabetes have intermediate values for various indices 
of LV systolic and diastolic function between normal 
and diabetic states [6, 28]. In addition, an association 
of prediabetes with other types of target organ dam-
age, such as carotid atherosclerosis and arterial stiff-
ness, has been reported, independent of other potential 
metabolic risk factors [7, 29]. As a result, although the 
clinical significance of early subclinical changes in the 
CV system observed in the prediabetic population has 
been in question in previous cross-sectional studies, the 
prognostic impact of LV diastolic dysfunction in pre-
diabetes from our findings supports the hypothesis that 
preclinical target organ damage may be predictive of T2D 
development.
Although the exact mechanism linking the impair-
ment of LV diastolic function to incident T2D in predia-
betic individuals could not be determined in the current 
analysis, it can be hypothesized that the disturbance of 
myocardial insulin signaling plays an important role in 
its pathogenesis [30]. Similar to the relationship between 
insulin resistance and its associated CV complications in 
overt T2D, recent studies have indicated that higher lev-
els of insulin resistance were related to the impairment 
of cardiac and vascular function compared to those with 
lower insulin resistance in a non-diabetic population 
[31, 32]. Therefore, considering that insulin resistance is 
a characteristic feature of T2D, and that higher levels of 
HOMA index were associated with incident T2D, our 
suggestion that prediabetic subjects with LV diastolic 
dysfunction are at higher risk of developing overt T2D 
appears plausible.
Limitations
Our study has several limitations. Firstly, not all of the 
parameters for the precise evaluation of LV diastolic 
function were measured. Therefore, although previous 
studies reported a wide range of the prevalence of LV 
Table 4 Echocardiographic predictors of incident type 2 diabetes in a subgroup stratified according to baseline glucose 
metabolism (NGM vs. prediabetes), adjusting for age, sex, BMI ≥23 kg/m2, fasting plasma glucose, 2-h plasma glucose, 
hypertension, statin therapy, family history of diabetes, smoking status, alcohol intake, HOMA-IR, total cholesterol, TG/
HDL ratio, and hsCRP: multivariate logistic regression analyses
BMI body mass index, CI confidence interval, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment-insulin resistance, hsCRP high sensitivity 
C-reactive protein, LV left ventricle, NGM normal glucose metabolism, OR odds ratio, TDI tissue Doppler imaging, TG triglycerides
a Corrected P values using Bonferroni method for multiple comparisons
Variables NGM (n = 788) Prediabetes (n = 1029)
OR (95% CI) P value P valuea OR (95% CI) P value P valuea
LA volume index (mL/m2) 1.037 (0.982–1.095) 0.190 1.000 1.021 (0.993–1.048) 0.140 1.000
LV mass index (g/m2) 0.999 (0.973–1.026) 0.948 1.000 1.014 (1.004–1.025) 0.009 0.126
LV hypertrophy (yes vs. no) 0.848 (0.268–2.683) 0.779 1.000 1.315 (0.833–2.074) 0.240 1.000
TDI Sm velocity (cm/s) 0.892 (0.633–1.257) 0.513 1.000 0.872 (0.764–0.995) 0.041 0.574
TDI Em velocity (cm/s) 0.958 (0.725–1.267) 0.765 1.000 0.864 (0.770–0.968) 0.012 0.168
E/Em ratio 1.078 (0.900–1.292) 0.416 1.000 1.064 (1.000–1.134) 0.051 0.714
LV diastolic dysfunction (yes vs. no) 1.000 (0.389–2.575) 0.999 1.000 1.906 (1.335–2.721) <0.001 0.005
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diastolic dysfunction ranging from 11.1 to 34.7% in the 
general population [33], the prevalence (37.5%) of LV 
diastolic dysfunction as determined in our study seems 
somewhat high. Nevertheless, given that each measured 
value for assessing LV diastolic function was an inde-
pendent predictor of incident T2D, the arbitrary defini-
tion of LV diastolic dysfunction used in our study seems 
acceptable. Another limitation is that since our cohort 
members were all Korean, so to apply our findings to 
other ethnicities may not be valid. Thus, additional 
research is required.
Conclusions
Left ventricular diastolic parameters and the presence 
of LV diastolic dysfunction were independent predictors 
of 6-year incident T2D in a population-based sample 
without overt CVD. These findings may have potential 
clinical implications for primary CV prevention because 
early identification of LV diastolic dysfunction could offer 
substantial opportunities to delay the development of 
T2D through more aggressive and preventive strategies, 
especially in the prediabetic population at high risk for 
developing T2D. Although the current guidelines do not 
recommend the routine use of screening tests to search 
for asymptomatic target organ damage in non-diabetic 
individuals, our study suggest that cardiac ultrasound 
may be a useful screening tool in a clinical practice. 
Future trials are needed to determine whether earlier and 
more aggressive intervention could prevent or delay the 
development of T2D in these individuals.
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